Emanuela Felley-Bosco

Group Emanuela Felley-Bosco

Emanuela Felley-Bosco, Forschungslabor, Molekulare Onkologie, Häldeliweg 4
8091 Zürich, Email: emanuela.felley-bosco@usz.ch, Tel. 044 634 28 56

Despite the ban on the commercial use of asbestos in the early nineties, the incidence of malignant pleural mesothelioma in Western Europe will continue to rise over the next decade because of the latency period of up to 40 years. Since the initiation of a multimodality approach including neoadjuvant chemotherapy and extrapleural pneumonectomy, the Clinic for Thoracic Surgery and the Clinic for Oncology at the University Hospital of Zürich have become the major referral center for patients with malignant pleural mesothelioma in Switzerland. The laboratory of Molecular Oncology, belonging to the Clinic for Oncology, has a longtime focus on translational research in thoracic malignancies. Because of the unique opportunity provided by our clinical activities in mesothelioma, we are currently focusing the research efforts of our laboratory in translational and innovative projects in malignant mesothelioma.

- From asbestos-exposure to cancer: a systemic approach to detect loss of
  homeostatic control in the mesothelial environment

- Preclinical Malignant Pleural Mesothelioma Models To Accelerate Clinical
  Research On Targeted Therapie

- Fighting against immune escape in Malignant Pleural Mesothelioma


1. Andreas Rusch, Gabriela Ziltener, Kristiaan Nackaerts, Walter Weder , Rolf A. Stahel, Emanuela Felley-Bosco, Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases. Lung Cancer. 2015 Jan;87(1):77-9. doi: 10.1016

2. R. A. Stahel, W. Weder, E. Felley-Bosco, U. Petrausch, A. Curioni-Fontecedro, I. Schmitt-Opitz, and S. Peters Searching for targets for the systemic therapy of mesothelioma. Annals of oncology, 2015

3. I N. Kotov, E. Siebring - van Olst, P. A. Knobel, I H. van der Meulen-Muileman, E Felley-Bosco , V W. van Beusechem, E F. Smitb, R A. Stahela and T M. Marti. Whole genome RNAi screens reveal a critical role of REV3 in coping with replication stress. Molecular Oncology, Mol Oncol. 2014 Jul 22. pii: S1574-7891(14)00163-X. doi: 10.1016/j.molonc

4. Renganathan A, Kresoja-Rakic J, Echeverry N, Ziltener G, Vrugt B, Opitz I, Stahel RA & Felley-Bosco E. GAS5 long non-coding RNA in malignant pleural mesothelioma. Molecular cancer, 05/2014; 13(1):119. DOI:10.1186/1476-4598-13-119

5. Otterstrom C, Soltermann A, Opitz I, Felley-Bosco E, Weder W, Stahel RA, Triponez F, Robert JH & Serre-Beinier V. CD74: a new prognostic factor for patients with malignant pleural mesothelioma. British journal of cancer, 2014 ,110:2040-6

6. Bitanihirwe KY, Meerang M, Friess M, Soltermann A, Frischknecht L, Thies S, Felley-Bosco E, Tsao MS, Allo G, de Perrot M, Seifert B, Moch H, Stahel R, Weder & W, Opitz I. PI3K/mTOR Signaling in Mesothelioma Patients Treated with Induction Chemotherapy Followed by Extrapleural Pneumonectomy,
J Thorac Oncol. 2014 Feb;9(2):239-47

7. Felley-Bosco E & Stahel R. Hippo/YAP pathway for targeted therapy. Transl Lung Cancer Res 2014;3(2):75-83

8. Cerciello F, Choi M, Nicastri A, Bausch-Fluck D, Ziegler A, Vitek O, Felley-Bosco E, Stahel R, Aebersold R & Wollscheid B. Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by Selected Reaction Monitoring. Clinical Proteomics 2013, 10:16 doi:10.1186/1559-0275-10-16

9. Nuber N, Curioni A, Dannenmann SR, Matter C, Von Boehmer L, Atanackovic D, Knuth A & Van den Broek M. LEUKEMIA. MAGE-C1/CT7 spontaneously triggers a CD4+ T-cell response in multiple myeloma patients. 2013 Aug;27(8):1767-9.

10. Shi Y, Moura U, Opitz I, Soltermann A, Rehrauer H, Thies S, Weder W, Stahel R & Felley-Bosco E. Role of hedgehog signaling in malignant pleural mesothelioma, Clinical Cancer Research, 2012 18:4646-56

11. Fischer B, Frei C, Moura U, Stahel R & Felley-Bosco E. Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy, Lung cancer, 2012 78:23-9